MedTrace Logo

A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases

NCT07143045 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2026-02-09

No results posted yet for this study

Summary

This study is a patient-centered, two-group, three-cohort, multi-center, prospective study to further evaluate the survival benefits and safety of zorifertinib as a first-line treatment in EGFRm+ advanced NSCLC patients with CNS metastases, and to compare the clinical value of zorifertinib with other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).

Conditions

  • EGFR Mutant Advanced Non-small Cell Lung Cancer
  • Central Nervous System (CNS) Metastases

Interventions

DRUG

zorifertinib

Cohort A and B will receive zorifertinib as first line treatment

Sponsors & Collaborators

  • Alpha Biopharma (Jiangsu) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yilong Wu M.D. · Guangdong Provincial People's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-29
Primary Completion
2031-05-31
Completion
2031-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07143045 on ClinicalTrials.gov